Molecular Partners (NASDAQ:MOLN) & Inhibrx (NASDAQ:INBX) Critical Analysis

Inhibrx (NASDAQ:INBX) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Profitability

This table compares Inhibrx and Molecular Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx	N/A	N/A	N/A
Molecular Partners	-1,043.01%	-39.31%	-35.46%

Valuation and Earnings

This table compares Inhibrx and Molecular Partners”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	$1.63 million	139.56	-$154.96 million	N/A	N/A
Molecular Partners	$7.84 million	27.00	-$69.04 million	($2.15)	-2.68

Molecular Partners has higher revenue and earnings than Inhibrx.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Inhibrx and Molecular Partners, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0	2	0	0	2.00
Molecular Partners	0	1	0	1	3.00

Inhibrx currently has a consensus price target of $27.00, indicating a potential upside of 71.87%. Molecular Partners has a consensus price target of $4.50, indicating a potential downside of 22.01%. Given Inhibrx’s higher possible upside, equities research analysts plainly believe Inhibrx is more favorable than Molecular Partners.

Insider & Institutional Ownership

82.5% of Inhibrx shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Inhibrx beats Molecular Partners on 6 of the 11 factors compared between the two stocks.

About Inhibrx

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.